Ionizing Radiation-Induced DNA damage repair
Ionizing Radiation-Induced DNA damage repair
批准号:
10237352
负责人:
Yilun Liu
金额:
$41.8万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2024-08-31
关键词:
ApoptosisBRCA mutationsBRCA1 MutationBRCA2 MutationBackBiological MarkersCell Cycle ArrestCell Cycle ProgressionCellsChemical StructureChemotherapy and/or radiationClinical ResearchClinical TreatmentClinical TrialsDNADNA DamageDNA Double Strand BreakDNA RepairDNA Sequence AlterationDefectDouble Strand Break RepairFDA approvedGrowthImpairmentIn VitroIonizing radiationLeadLesionMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMolecularNAD+ kinaseNADPNormal CellPhosphoric Monoester HydrolasesPhosphorylationPost-Translational Protein ProcessingRadiation induced double strand breakRadiation therapyRegulationResearch Project GrantsRoleSignal TransductionStructureTestingTherapeuticTreatment-Related Cancercancer cellcancer therapychemotherapydesignexperimental studyin vivoinhibitor/antagonistneoplastic cellnovelnovel therapeutic interventionovarian neoplasmpotential biomarkerrecruitrepairedresponsesensortriple-negative invasive breast carcinomatumortumor DNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PARP inhibitors have been used in the clinical treatment for tumors with BRCA1 or BRCA2 mutations. The
major function of PARP inhibitors is to suppress PARP1 and PARP2 mediated poly(ADP-ribosyl)ation, a
unique posttranslational modification, mainly induced in DNA damage. Suppression of PARylation by PARP
inhibitors abolishes early recruitment of DNA damage response factors and impairs DNA damage repair.
Because PARylation is a very transient posttranslational modification, normal cells have other repair
mechanism to compensate for the loss of PARylation-dependent DNA damage response. However, a set of
tumor cells harbor genetic mutations, such as BRCA1/2 mutations, which have already led to impaired DSB
repair. With additional PARP inhibitor treatment to abolish PARylation-dependent DNA damage response,
these tumor cells will undergo apoptosis. Thus, PARP inhibitor treatment selectively kills tumor cells with DNA
damage repair defects, such as BRCA tumors.
However, recent clinical trials suggest that only a set of BRCA tumors respond effectively to the PARP
inhibitor treatment. Moreover, accumulated evidence indicates that PARP inhibitor treatment is able to
suppress the growth of other types of tumor besides BRCA tumors. Thus, to extend the therapeutic potential of
PARP inhibitors in cancer treatment, we explored biomarkers for the PARP inhibitor treatment. Interestingly,
we found that NADP+, an NAD+ derivative, can suppress the activity of PARPs both in vitro and in vivo. Thus,
we hypothesize that NADP+ is an endogenous PARP inhibitor, and the high level of NADP+ in tumor cells is
able to sensitize tumor cells for DNA damaging related cancer therapy, including chemotherapy and radiation
therapy. In this application, we plan to examine 1) the role of NADP+ in poly(ADP-ribosyl)ation-dependent DNA
damage repair; 2) the molecular mechanism that regulates the cellular level of NADP+; 3) the role of NADP+ in
sensitizing tumor cells to DNA damaging-associated cancer therapy.
Taken together, the proposed study will not only reveal novel molecular mechanism in DNA damage repair,
but also identify novel therapeutic approach for cancer treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECQ5-dependent SUMO2 conjugation of PCNA in the resolution of transcription-replication conflicts
-
批准号:10328909
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Yilun Liu
-
依托单位:
RECQ5-dependent SUMO2 conjugation of PCNA in the resolution of transcription-replication conflicts
-
批准号:10558750
-
项目类别:
-
资助金额:$38.78万
-
财政年份:2019
-
负责人:Yilun Liu
-
依托单位:
The function of Topoisomerase I SUMOylation in transcription and chemoresistance
-
批准号:9901592
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2018
-
负责人:Yilun Liu
-
依托单位:
The function of Topoisomerase I SUMOylation in transcription and chemoresistance
-
批准号:10132345
-
项目类别:
-
资助金额:$34.6万
-
财政年份:2018
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8371475
-
项目类别:
-
资助金额:$26.34万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8101561
-
项目类别:
-
资助金额:$8.4万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8228028
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8811101
-
项目类别:
-
资助金额:$34.86万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8444281
-
项目类别:
-
资助金额:$32.77万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
The molecular basis of RECQ4-associated genetic disorders and cancer predispositi
-
批准号:8623102
-
项目类别:
-
资助金额:$33.81万
-
财政年份:2011
-
负责人:Yilun Liu
-
依托单位:
Ionizing Radiation-Induced DNA damage repair
-
批准号:10475652
-
项目类别:
-
资助金额:$40.96万
-
财政年份:2009
-
负责人:Yilun Liu
-
依托单位:
Ionizing Radiation-Induced DNA damage repair
-
批准号:10687029
-
项目类别:
-
资助金额:$41.8万
-
财政年份:2009
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:8119644
-
项目类别:
-
资助金额:$2.61万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:7529332
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:8300189
-
项目类别:
-
资助金额:$27.05万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:7663891
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:8371419
-
项目类别:
-
资助金额:$24.4万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
Understanding the role of RAD51C complexes in recombination and repair
-
批准号:7904108
-
项目类别:
-
资助金额:$27.47万
-
财政年份:2008
-
负责人:Yilun Liu
-
依托单位:
海外基金